Scisparc Ltd (SPRC)

$5.08 +0.13 (2.63%)
Market Cap 2.87M
Revenue (ttm) 860,000.00
Net Income (ttm) -12.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,416.28%
Debt to Equity Ratio 0.07
Volume 11,500
Avg Vol 226,038
Day's Range N/A - N/A
Shares Out 566,000.00
Stochastic %K 12%
Beta 2.81
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially man...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv-Yafo, Israel
ValuePrince
ValuePrince Sep. 14 at 1:41 AM
$SPRC 🎙️
0 · Reply
DrUser
DrUser Sep. 4 at 4:37 PM
$SPRC 👀
0 · Reply
simplifocused
simplifocused Sep. 4 at 12:31 PM
$SPRC Another gem I care about for a squeeze, NFA
0 · Reply
focafoca99
focafoca99 Sep. 2 at 8:24 PM
$SPRC flags an FDA orphan-drug push for an adult Tourette drug as SCI-210 autism trial enrollment gains momentum.
0 · Reply
STACKD0E
STACKD0E Sep. 2 at 12:19 PM
$SPRC 👁
0 · Reply
MrTicker
MrTicker Sep. 2 at 12:19 PM
$SPRC SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies GLOBENEWSWIRE 7:17 AM ET 9/2/2026
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 2 at 12:17 PM
$SPRC SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
0 · Reply
simplifocused
simplifocused Aug. 31 at 8:19 PM
$SPRC $500 let's gooooo...nfa
0 · Reply
Alphaindia
Alphaindia Aug. 31 at 8:19 PM
$SPRC Could run any moment!!! 500k float
0 · Reply
STACKD0E
STACKD0E Aug. 31 at 8:12 PM
$BBIO $ONC $HIMS $SPRC 👁️
0 · Reply
Latest News on SPRC
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

Sep 2, 2026, 5:30 PM EDT - 11 days ago

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

Sep 2, 2026, 8:10 AM EDT - 11 days ago

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc subsidiary provides update on SCI-210 trial enrollment

2026-08-31T20:10:46.000Z - 13 days ago

SciSparc subsidiary provides update on SCI-210 trial enrollment

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Aug 31, 2026, 4:03 PM EDT - 13 days ago

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Aug 31, 2026, 4:00 PM EDT - 13 days ago

NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Neurothera Labs Inc. Announces Share Consolidation

Aug 28, 2026, 5:05 PM EDT - 16 days ago

Neurothera Labs Inc. Announces Share Consolidation

Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment

2026-08-27T16:10:15.000Z - 17 days ago

Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment

CMND IXHL JUNS

NeuroThera Labs Engages Dr. Reuter Investor Relations

Aug 27, 2026, 8:00 AM EDT - 17 days ago

NeuroThera Labs Engages Dr. Reuter Investor Relations

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

Aug 26, 2026, 8:32 AM EDT - 18 days ago

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination

2026-08-24T13:20:13.000Z - 20 days ago

SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination

CMND

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Aug 24, 2026, 8:51 AM EDT - 20 days ago

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million

Aug 18, 2026, 8:06 AM EDT - 26 days ago

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million

Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement

Aug 17, 2026, 9:10 PM EDT - 27 days ago

Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement

NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement

Aug 12, 2026, 5:00 PM EDT - 4 weeks ago

NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement

SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

Aug 12, 2026, 8:25 AM EDT - 4 weeks ago

SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

Aug 12, 2026, 8:02 AM EDT - 4 weeks ago

NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

Aug 5, 2026, 8:22 AM EDT - 5 weeks ago

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

Aug 5, 2026, 8:05 AM EDT - 5 weeks ago

NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

Jul 31, 2026, 8:20 AM EDT - 6 weeks ago

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

Scisparc Ltd trading resumes

2026-07-29T14:00:47.000Z - 6 weeks ago

Scisparc Ltd trading resumes

Scisparc Ltd trading halted, volatility trading pause

2026-07-29T13:56:02.000Z - 6 weeks ago

Scisparc Ltd trading halted, volatility trading pause

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

Jul 29, 2026, 8:32 AM EDT - 6 weeks ago

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

SciSparc to target agentic artificial intelligence market

2026-07-27T13:16:01.000Z - 6 weeks ago

SciSparc to target agentic artificial intelligence market

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

Jul 27, 2026, 8:25 AM EDT - 6 weeks ago

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

SciSparc initiates SCI-110 clinical trial in Germany

2026-07-15T13:06:01.000Z - 2 months ago

SciSparc initiates SCI-110 clinical trial in Germany

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Jul 15, 2026, 8:41 AM EDT - 2 months ago

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Jul 15, 2026, 8:31 AM EDT - 2 months ago

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

TS

NeuroThera Labs Announces Upsize to Private Placement

Jul 2, 2026, 5:30 PM EDT - 2 months ago

NeuroThera Labs Announces Upsize to Private Placement

NeuroThera Labs Announces C$5,000,000 Private Placement of Units

Jun 30, 2026, 6:00 PM EDT - 2 months ago

NeuroThera Labs Announces C$5,000,000 Private Placement of Units

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

Jun 4, 2026, 7:32 AM EDT - 3 months ago

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.

Jun 3, 2026, 5:15 PM EDT - 3 months ago

Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

May 28, 2026, 8:40 AM EDT - 3 months ago

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

Neurothera Labs Announces Adoption of Semi-Annual Reporting

May 20, 2026, 5:00 PM EDT - 3 months ago

Neurothera Labs Announces Adoption of Semi-Annual Reporting

Neurothera Labs Announces Continuance into Ontario

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Neurothera Labs Announces Continuance into Ontario

Neurothera Labs Engages bullVestor for Investor Relations Activities

Apr 23, 2026, 6:00 PM EDT - 4 months ago

Neurothera Labs Engages bullVestor for Investor Relations Activities

SciSparc discloses patent application for depression yherapy

2026-03-16T12:25:23.000Z - 6 months ago

SciSparc discloses patent application for depression yherapy

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 16, 2026, 8:20 AM EDT - 6 months ago

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc’s Neurothera Labs announces publication of international patent

2026-03-12T12:01:25.000Z - 6 months ago

SciSparc’s Neurothera Labs announces publication of international patent

CMND

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 12, 2026, 7:55 AM EDT - 6 months ago

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

2026-03-10T13:38:10.000Z - 6 months ago

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Mar 10, 2026, 9:28 AM EDT - 6 months ago

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 6 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

CMND

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

Mar 10, 2026, 7:30 AM EDT - 6 months ago

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

Scisparc Ltd trading halted, news pending

2026-03-04T00:50:09.000Z - 6 months ago

Scisparc Ltd trading halted, news pending

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:35:06.000Z - 6 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:28:37.000Z - 6 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:23:28.000Z - 6 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc Announces 1-for-9 Reverse Share Split

Mar 2, 2026, 8:00 AM EST - 6 months ago

SciSparc Announces 1-for-9 Reverse Share Split

SciSparc files to sell 23.04M ordinary shares for holders

2026-02-17T22:30:16.000Z - 6 months ago

SciSparc files to sell 23.04M ordinary shares for holders

SciSparc files $50M mixed securities shelf

2026-02-03T21:40:29.000Z - 7 months ago

SciSparc files $50M mixed securities shelf

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:24 AM EST - 7 months ago

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:00 AM EST - 7 months ago

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

Jan 26, 2026, 8:13 AM EST - 7 months ago

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

Jan 13, 2026, 6:55 AM EST - 8 months ago

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Jan 12, 2026, 4:02 PM EST - 8 months ago

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Neurothera Labs Announces Results of AGM

Jan 8, 2026, 6:00 PM EST - 8 months ago

Neurothera Labs Announces Results of AGM

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:17 AM EST - 8 months ago

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:00 AM EST - 8 months ago

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 9:29 AM EST - 9 months ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 9 months ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Dec 1, 2025, 8:32 AM EST - 9 months ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 26, 2025, 7:38 AM EST - 9 months ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 20, 2025, 6:42 AM EST - 9 months ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 9 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 10 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 10 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

ValuePrince
ValuePrince Sep. 14 at 1:41 AM
$SPRC 🎙️
0 · Reply
DrUser
DrUser Sep. 4 at 4:37 PM
$SPRC 👀
0 · Reply
simplifocused
simplifocused Sep. 4 at 12:31 PM
$SPRC Another gem I care about for a squeeze, NFA
0 · Reply
focafoca99
focafoca99 Sep. 2 at 8:24 PM
$SPRC flags an FDA orphan-drug push for an adult Tourette drug as SCI-210 autism trial enrollment gains momentum.
0 · Reply
STACKD0E
STACKD0E Sep. 2 at 12:19 PM
$SPRC 👁
0 · Reply
MrTicker
MrTicker Sep. 2 at 12:19 PM
$SPRC SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies GLOBENEWSWIRE 7:17 AM ET 9/2/2026
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 2 at 12:17 PM
$SPRC SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
0 · Reply
simplifocused
simplifocused Aug. 31 at 8:19 PM
$SPRC $500 let's gooooo...nfa
0 · Reply
Alphaindia
Alphaindia Aug. 31 at 8:19 PM
$SPRC Could run any moment!!! 500k float
0 · Reply
STACKD0E
STACKD0E Aug. 31 at 8:12 PM
$BBIO $ONC $HIMS $SPRC 👁️
0 · Reply
focafoca99
focafoca99 Aug. 26 at 12:52 PM
$SPRC recruited AI luminary Prof. Carmel Domshlak to its new Scientific Advisory Board, bolstering its Agentic AI strategy.
0 · Reply
MrTicker
MrTicker Aug. 26 at 12:33 PM
$SPRC SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board GLOBENEWSWIRE 7:32 AM ET 8/26/2026
0 · Reply
focafoca99
focafoca99 Aug. 24 at 1:04 PM
$SPRC recorded a US patent publication for its MDMA-PEA combo from the NeuroThera-Clearmind partnership.
0 · Reply
MrTicker
MrTicker Aug. 24 at 12:55 PM
$CMND $SPRC SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders BENZINGA 7:54 AM ET 8/24/2026
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 24 at 12:51 PM
$SPRC SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
0 · Reply
TA_Kongen
TA_Kongen Aug. 18 at 5:05 PM
$OPTH On watch now. Along with $CMND $PBM $SPRC
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 18 at 12:06 PM
$SPRC SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Aug. 12 at 1:52 PM
$SPRC Violation / Rape / Knife
0 · Reply
race2zero
race2zero Aug. 12 at 1:32 PM
$SPRC $7 to $6.10 quick short, I’m out
0 · Reply
race2zero
race2zero Aug. 12 at 12:48 PM
$SPRC
0 · Reply
premarketmaker
premarketmaker Aug. 12 at 12:46 PM
$SPRC the big squeeze would be up at $15.79
0 · Reply